|
|
Volumn 97, Issue 10, 2005, Pages 710-711
|
|
NCCN guidelines advocate wider use of colony-stimulating factor
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTIBIOTIC AGENT;
DOCETAXEL;
PLACEBO;
RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;
ANTINEOPLASTIC AGENT;
COLONY STIMULATING FACTOR;
AGE;
BREAST CANCER;
CLINICAL TRIAL;
COMORBIDITY;
COST EFFECTIVENESS ANALYSIS;
DECISION MAKING;
DISEASE ASSOCIATION;
DRUG COST;
DRUG DOSE REDUCTION;
DRUG EFFICACY;
EVIDENCE BASED MEDICINE;
FEASIBILITY STUDY;
FEBRILE NEUTROPENIA;
HEALTH CARE COST;
HIGH RISK PATIENT;
HOSPITALIZATION;
HUMAN;
INCIDENCE;
MEDICAL DECISION MAKING;
MEDICAL SOCIETY;
NOTE;
PRACTICE GUIDELINE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
RISK FACTOR;
RISK REDUCTION;
TREATMENT OUTCOME;
UNITED STATES;
ARTICLE;
CHEMICALLY INDUCED DISORDER;
CONSENSUS;
FEVER;
NEOPLASM;
NEUTROPENIA;
PRESCRIPTION;
STANDARD;
STATISTICS;
ANTINEOPLASTIC AGENTS;
COLONY-STIMULATING FACTORS;
CONSENSUS;
EVIDENCE-BASED MEDICINE;
FEVER;
FILGRASTIM;
HUMANS;
NEOPLASMS;
NEUTROPENIA;
PRACTICE GUIDELINES;
PRESCRIPTIONS, DRUG;
RISK ASSESSMENT;
UNITED STATES;
|
|
EID: 20544464682
PISSN: 00278874
EISSN: None
Source Type: Journal
DOI: 10.1093/jnci/97.10.710 Document Type: Note |
|
Times cited : (9)
|
|
References (0)
|